Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2015-03-22 Investor Presentation
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
RGS to present at Regenerative Medicine Investor Day 2 pages 199.8KB
Investor Presentation Classification · 90% confidence The document is a press release announcing that Regeneus Ltd will present at the 3rd Annual Regenerative Medicine Investor Day on March 25, 2015. It provides details about the event, the company's presentation schedule, and background information about the company and the event organizer. There is no financial data, no report attached or referenced as being published, and no regulatory filing or certification. The document is an announcement of an upcoming investor presentation event, not the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included, the document is about the presentation event.
2015-03-22 English
Positive preclinical results for Progenza 2 pages 202.6KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing positive preclinical results for a cell therapy treatment by Regeneus. It discusses study outcomes, plans for clinical trials, and company background. There is no financial data, regulatory filing, or detailed report content. It is an announcement of scientific and clinical progress rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about product development progress, which aligns best with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2015-03-08 English
New Director joins Regeneus Board of Directors 1 pa
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 23 February 2015, announcing the appointment of a new independent non-executive director to the Board of Regeneus Ltd. It focuses on the change in the company's board composition and provides background on the new director. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other types of filings. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2015-02-22 English
Regeneus Half-Yearly Appendix 4D and Accounts 23 pages 645.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Half Year Report for 6 months to 31 December 2014' and references the Corporations Act 2001 and ASX Rule 4.2.A.3, which pertains to half-year financial reporting. It contains detailed financial statements including profit or loss, financial position, cash flows, notes to the financial statements, directors' report, and auditor's review report. The content includes comprehensive financial data and analysis for a six-month period, which is shorter than a full fiscal year. The document also discusses operational results, capital raising, and other business activities during the half-year period. Given the detailed interim financial statements and analysis, this document fits the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary but a full report with substantive financial data and management discussion for the half-year period ending 31 December 2014. H1 2015
2015-02-18 English
Regeneus Half-Year Announcement 2 pages 198.2KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Regeneus 2015 Half-Year Results' and reports financial results for the half-year ended 31 December 2014. It includes financial highlights such as revenues, net loss, cash flows, and cash position, as well as operational updates and future plans. The document length is 3210 characters, which is relatively short but contains substantive financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement of a report or a certification, but a summary of half-year financial results and business progress. Therefore, the appropriate classification is IR (Interim / Quarterly Report). H1 2015
2015-02-18 English
Appendix 4C - Q2 FY15 5 pages 199.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, operating cash flows, investing and financing activities, and reconciliation of cash. The presence of quarterly financial data and cash flow statements indicates this is a periodic financial report for a quarter. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2015
2015-01-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.